What is HC Wainwright’s Estimate for XENE FY2027 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at HC Wainwright cut their FY2027 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Tuesday, March 10th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings of ($6.05) per share for the year, down from their prior forecast of ($6.00). HC Wainwright has a “Buy” rating and a $74.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ FY2028 earnings at ($4.97) EPS, FY2029 earnings at ($3.06) EPS and FY2030 earnings at ($0.75) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the company earned ($0.84) EPS.

Several other research firms have also weighed in on XENE. Needham & Company LLC upped their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Company raised their target price on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Wedbush upped their price target on Xenon Pharmaceuticals from $47.00 to $64.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Wolfe Research assumed coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $71.94.

Xenon Pharmaceuticals Stock Down 2.6%

NASDAQ XENE opened at $59.04 on Thursday. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $63.95. The stock has a market cap of $4.91 billion, a P/E ratio of -13.54 and a beta of 0.91. The company’s 50-day simple moving average is $43.23 and its 200 day simple moving average is $41.69.

Insider Activity

In related news, insider Andrea Difabio sold 2,607 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the completion of the sale, the insider directly owned 4,893 shares of the company’s stock, valued at $294,118.23. This trade represents a 34.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $361,980. The trade was a 97.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 326,647 shares of company stock worth $19,066,951. Insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Several large investors have recently made changes to their positions in XENE. Goldman Sachs Group Inc. lifted its position in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after buying an additional 32,486 shares in the last quarter. Bank of New York Mellon Corp increased its position in Xenon Pharmaceuticals by 73.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 436,020 shares of the biopharmaceutical company’s stock valued at $13,647,000 after acquiring an additional 184,873 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $577,000. Nan Fung Trinity HK Ltd. bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $4,964,000. Finally, Geode Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock worth $30,369,000 after purchasing an additional 900,746 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 X‑TOLE2 readout: azetukalner met its goal by significantly reducing focal‑onset seizure frequency; Xenon now plans an NDA filing in 3Q‑2026 — a clear near‑term commercialization catalyst. Zacks: Azetukalner Phase 3
• Positive Sentiment: Multiple brokerages raised ratings/targets after recent data: Deutsche Bank to $90, HC Wainwright to $74, Wells Fargo to $68, Wedbush to $64 (and others). Upgrades add momentum and institutional validation for XENE’s pathway to commercialization. Deutsche Bank price target raise HC Wainwright price target raise
• Positive Sentiment: HC Wainwright materially raised its longer‑term EPS runway (notably FY2030 estimate moved much closer to break‑even), and reiterated a Buy rating — signals improving sell‑side expectations for future profitability. HC Wainwright research note
• Neutral Sentiment: Upsized public offering priced: Xenon priced ~10.53M common shares (plus pre‑funded warrants) at $57/sh to raise approx. $650M (underwriters have a 30‑day option for additional shares). This meaningfully boosts cash runway for Phase‑3/NDAs but completion and market reception remain execution items. GlobeNewswire: Offering details
• Neutral Sentiment: Some mixed FY estimate moves from HC Wainwright (small FY2027 tweak down but bigger improvements in later years) — indicates analysts are reworking multi‑year cash‑flow and approval assumptions as new data and financing details emerge. HC Wainwright estimates
• Negative Sentiment: Insider selling: CEO Ian Mortimer and multiple insiders disclosed large open‑market sales in early March (CEO sold 270k shares at ~\$60.33 and additional transactions), which may concern some investors about timing/intent and can add selling pressure. SEC insider filing
• Negative Sentiment: Dilution risk: the large offering increases share count and could weigh on near‑term per‑share metrics and the stock price until proceeds are visibly deployed to value‑creating milestones. Offering press release

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.